anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The proposed multi-center clinical trial would engage the same collaborative team that successfully operationalized COMIT I, namely, the Richardson Centre for Functional Foods and Nutraceuticals (RCFFN) at the University of Manitoba (Winnipeg, Manitoba, Canada), the L'Institut Des Nutraceutiques et des Aliments Fonctionnels (INAF) at Laval University (Quebec City, Quebec, Canada), the Department of Nutritional Sciences at The Pennsylvania State University (University Park, Pennsylvania, USA), the Risk Factor Modification Centre at St. Michael's Hospital (Toronto, Ontario, Canada). St. Boniface Hospital Research (Winnipeg, Manitoba, Canada) will be an additional clinical trial site. The proposed COMIT II research program will proceed as a double blind, randomized crossover study consisting of three treatment phases of six weeks, each separated by a 6-week washout period. Participants will consume a fixed composition of a precisely controlled basal, weight-maintaining diet (35% energy from fat, 50% carbohydrate and 15% protein) supplemented with the following treatment oils: (a) regular canola oil, (b) high stability/ high oleic canola oil and (c) a typical "Western diet" fat intake as a control treatment comprised largely of saturated fat with substantial levels of omega-6 linoleic acid, common to current North American intakes. Treatment oils will be isocalorically incorporated into fruit smoothies made with milk and consumed at breakfast and supper. The clinical segment of COMIT II is expected to be completed by the mid to end of the second year, with sample analyses to be completed by the end of year three.
RATIONALE: Healthcare systems remain disease oriented despite growing sustainability concerns caused by inadequate management of patients with multimorbidity. Comprehensive care programmes (CCPs) can play an important role in streamlining care delivery, but large differences in setup and results hinder firm conclusions on their effectiveness. Many elements for successful implementation of CCPs are identified, but strategies to overcome barriers and embed programmes within health systems remain unknown.
AIMS AND OBJECTIVES: To address this knowledge gap through a detailed study of implementing a CCP in a Dutch hospital setting, including patient experiences, facilitators, barriers and ways to overcome those barriers. Additionally, this study aims to explore effects on patient satisfaction and healthcare use.
METHODS: A qualitative study design with 39 semistructured interviews and focus groups between July 2020 and February 2023 with 16 patients and 17 involved professionals. Additionally, effects on quantitative outcomes for patient satisfaction (PACIC-20) and healthcare use were explored.
RESULTS: Professionals expressed a wide range of topics related to implementation and ways to overcome barriers at hospital and system level. Alterations in the design to accommodate varying care demands, focus on inclusions through referrals, and lack of long-term support and appropriate financing were key topics. Patients expressed varying experiences, stated a strong desire for comprehensive information, and emphasised the importance of trust in caregivers. Patient satisfaction showed no effects, while healthcare use showed slight decreases in trends, but patient numbers were limited.
CONCLUSION: The introduction of a CCP is feasible, and exploratory analysis on effectiveness shows lower hospital care use without decreasing patient satisfaction. However, this is accompanied by several challenges that show current fragmented systems still do not support implementation of integrated care initiatives. Overcoming those comes with substantial costs and may require a strong bottom-up implementation within a motivated team and actions on all levels of healthcare systems.
Same physical evaluation and blood sampling as the experimental group. The subjects will receive 1.5 grams per day of placebo (talc, the medium in which nicotinamide is prepared), orally, for 30 days. The bottle and the capsules will be of the same physical characteristics (shape, color, and flavor) in both groups. During that period, patients will assess patient adherence and possible adverse effects.
FIELD: biotechnology.SUBSTANCE: group of inventions relates to biotechnology and discloses an anti-inflammatory preparation based on mammalian spleen peptides, wherein the preparation is presented in the form of a dermal water-alcohol lotion of systemic anti-inflammatory action, containing a fraction of purified peptides of spleen of mammals with molecular weight of not more than 12 kDa in amount of 1÷5 wt. % to the total weight of the composition, 96 % ethanol in amount of 40 wt. %, sodium chloride in amount of 0–0.5 wt. %, zinc chloride in amount of 0–0.05 wt. %, calcium sulphate in amount of 0–0.2 wt. %, water is the rest, at pH 7.4 ± 0.2. Group of inventions also relates to a method of suppressing the inflammatory response and to the use of an anti-inflammatory preparation.EFFECT: achieving anti-inflammatory therapeutic effect with underlying permanent forced overexpression of the most powerful pro-inflammatory cytokine - tumour necrosis factor (TNF-alpha - TNFα), that is, the preparation according to the invention provides not only an anti-inflammatory effect, but also exhibits tolerogenic action - initiates specific tolerance of T-regulatory cells to body own antigens, which causes its effectiveness in therapy of autoimmune inflammatory diseases; more effective stimulation of immature (naive) monocytes to Treg production, compared to cytokines GM-CSF + M-CSF, which are used in the classical Treg induction technique and can be present in peptide fractions from the spleen with molecular weight of more than 12 kDa, specifically about 30 kDa for GM-CSF and about 60 kDa for M-CSF, but are absent in the disclosed preparation based on the spleen peptide fraction with molecular weight of not more than 12 kDa; achieving systemic anti-inflammatory therapeutic action when using the preparation in the form of a water-alcohol lotion when applied to the skin, which causes a decrease in the concentration of pro-inflammatory cytokines TNFa, IL-1b and IL-2 in the blood; prevention of development of psoriatic and rheumatoid arthritis with efficiency of about 70 % due to systemic tolerogenic anti-inflammatory therapeutic action; achieving a tolerogenic anti-inflammatory therapeutic effect in a form suitable for out-of-hospital use; achieving systemic tolerogenic anti-inflammatory therapeutic action without undesirable side effects - allergic reactions and suppression of adaptive immunity.14 cl, 2 tbl, 8 ex, 10 dwg
1275605 Fluorene dicarboxamide derivatives RICHARDSON-MERRELL Inc 30 Sept 1969 [11 Oct 1968] 48098/69 Heading C2C The invention relates to novel fluorenonefluorenolandfluorene-bis-basic dicarboxamides having the general formula wherein X is O, H 2  or H and OH, R 1  is H or (C 1 -C 6 ) alkyl, A is a (C 2 -C 8 ) alkylene chain, R 2  and R 3  are H, (C 1 -C 6 ) alkyl, (C 3 -C 6 ) cycloalkyl or (C 3 -C 6 ) alkenyl having the unsaturation other than in the 1-position, or is a saturated monocyclic heterocyclic ring having 4 or 5 ring carbon atoms, and also to acid addition salts of such compounds. The fluorene and fluorenone compounds of the invention may be prepared by condensing a compound of the formula with an aminoalkylamine of the formula wherein Y is OH or forms with its vicinal carbonyl group a reactive derivative of a carboxylic acid, e.g. a halide, ester or azolide. Alternatively a compound of the formula wherein hal is halogen, may be condensed with an amine of the formula Also, a compound of the formula may be reduced to give a fluorene or fluorenone derivative of the invention. The fluorenol derivatives may be prepared by reduction of the corresponding fluorenone. The compounds of the invention may be used as biocidal agents, and the salts thereof may be used as pharmaceutical agents.
First-degree relatives of patients with multiple myeloma are at increased risk for the disease, but the contribution of pathogenic germline variants (PGV) in hereditary cancer genes to multiple myeloma risk and outcomes is not well characterized. To address this, we analyzed germline exomes in two independent cohorts of 895 and 786 patients with multiple myeloma. PGVs were identified in 8.6% of the Discovery cohort and 11.5% of the Replication cohort, with a notable presence of high- or moderate-penetrance PGVs (associated with autosomal dominant cancer predisposition) in DNA repair genes (3.6% and 4.1%, respectively). PGVs in BRCA1 (OR = 3.9, FDR < 0.01) and BRCA2 (OR = 7.0, FDR < 0.001) were significantly enriched in patients with multiple myeloma when compared with 134,187 healthy controls. Five of the eight BRCA2 PGV carriers exhibited tumor-specific copy number loss in BRCA2, suggesting somatic loss of heterozygosity. PGVs associated with autosomal dominant cancer predisposition were associated with younger age at diagnosis, personal or familial cancer history, and longer progression-free survival after upfront high-dose melphalan and autologous stem-cell transplantation (P < 0.01). Significance: Our findings suggest up to 10% of patients with multiple myeloma may have an unsuspected cancer predisposition syndrome. Given familial implications and favorable outcomes with high-dose melphalan and autologous stem-cell transplantation in high-penetrance PGV carriers, genetic testing should be considered for young or newly diagnosed patients with a personal or family cancer history. See related commentary by Walker, p. 375.
Following topical application, tazarotene undergoes esterase hydrolysis to form its active metabolite, tazarotenic acid. Tazarotenic acid is highly bound to plasma proteins (greater than 99%).

Systemic exposure following topical application of ARAZLO was evaluated in 28 subjects in an open-label, randomized, pharmacokinetic study. Subjects aged 9 years and older with moderate to severe acne applied approximately 4 grams of ARAZLO to the entire face (excluding eyes and lips), neck, upper chest, upper back and shoulders once daily for 14 Days.

The majority of collected samples had concentrations below the limit of quantification (LOQ) for tazarotene (0.005 ng/mL). The mean C maxand mean AUC (0-t)values for tazarotene from quantifiable samples were 0.007 ng/mL and 0.164 ng•hr/mL on Day 14 to 15, respectively. The mean C maxand AUC (0-t)of tazarotene in subjects aged 9 to less than 12 years was approximately 3.7 and 3.6 fold higher, respectively, compared to that observed in subjects 12 years and older. 

Tazarotenic acid concentrations were measurable in the majority of samples following single and repeated topical administration of ARAZLO (LOQ = 0.005 ng/mL). The mean C maxand AUC (0-t)values for tazarotenic acid from quantifiable samples were 0.365 ng/mL and 5.72 ng•hr/mL on Days 14 to 15, respectively. The mean C maxand AUC (0-t)of tazarotenic acid in subjects aged 9 to less than 12 years was approximately 2.4 and 2.3 fold higher, respectively, compared to that observed in subjects 12 years and older.
PROBLEM TO BE SOLVED: To obtain both a lubricating agent for condom, safe to a human body, excellent in performances, capable of maintaining lubricating properties during use, containing a squalene and a condom stuck with the agent. SOLUTION: This agent comprises a powdery material containing one or more compounds selected from the group consisting of squalene, its partial hydrolyzate and squalane. Squalene is a polyunsaturated compound of the formula. The agent consists of 10-85wt.% of the squalene, 2-70wt.% of a protein, 5-7wt.% of a saccharide or a saccharide compound material and 0.1-20wt.% of an emulsifying agent and/or a stabilizer as main components. Since the lubricating agent comprises powder and the squalene, and the squalene is gradually released from the powder, moderate lubricating properties are obtained during use. Since the powder is mixed in the agent, handleability in the production of a condom is excellent. Squalene has cell activating effects, antiinflammatory effects and male and female hormone activating ability and is useful for a lubricating agent for condom.
Our proposal is to develop a sentinel syndromic surveillance strategy to identify encephalitis cases possibly related to emerging pathogens admitted to Intensive Care Units (ICUs) in Brazil. "Sentinel" to allow a diagnostic intensive approach on a smaller number of cases, "syndromic" to guarantee a sensitive criterion to include new or unexpected pathogens, and in ICUs to prioritize potentially severe threats. In a resource-limited setting it won't be possible to monitor and investigate all cases of encephalitis, so a cost-effective algorithm for early identification of the cases that are most likely to be caused by unusual, unexpected or emerging pathogens must be developed. As universal surveillance of encephalitis is not recommended in Brazil, data on incidence, causes and prognosis is not available, leaving a gap in the understanding of the epidemiology of this central nervous system disease in the country. This study will review cases of encephalitis admitted in the last five years to ICUs in a large metropolitan area. Its results will help understand the epidemiology of encephalitis in Brazil and will provide data to build a strategy for early identification of outbreaks and of emerging infectious diseases.

We will use data of a sentinel sample of 19 ICUs of nine of the largest hospitals in the metropolitan area of Rio de Janeiro - Brazil (12 million inhabitants in 2018), from 2015 to 2018, covered with the Epimed Monitor database, which routinely registers all admissions in ICUs. The Epimed Monitor system is present in more than 400 hospitals throughout Brazil, with 750 ICUs and 11,000 monitored beds, reaching over 1,000,000 patients within its base (http://www.utisbrasileiras.com.br/en/epimed/)(Zampieri et al. 2017). Based on previous studies (Boucher et al. 2017; Soares et al. 2011), we expect to identify between 100 and 250 cases of encephalitis.
Single dose: 1 tablet (128 mg). Multiple dose: 1 tablet (128 mg) 3 times a day for 3 days (first dose on an empty stomach, second and third two hours after meals), once in the morning on an empty stomach on day 4.
All participants will undergo the same schedule. Each participant will be fitted with a conventional and a 3D printed bolus prior to receiving radiation therapy. Each bolus will be assessed for optimal dose distribution of the radiation to the tumor through computer stimulation. The bolus, either conventional or 3D printed, that is found to be superior will be used for the actual radiation therapy treatment.
CHILDNEPH is an ongoing prospective longitudinal study of children with incident and prevalent nephrotic syndrome. Children are recruited from 12 centres across Canada and followed for at least 30 months. The project starting in August of 2013 with the goal of following 400 patients. Data is collected at enrollment, beginning and end of each relapse, semi-annual visits and end of study. Detailed prescription data is collected regarding glucocorticoids and all second line agents. All relapses are recorded with time to urinary remission of proteinuria.

The investigators are moving towards registry based trials to determine optimal treatment protocols for nephrotic syndrome with an overall goal to minimize glucocorticoid exposure, a patient priority.
Objective: To investigate the clinical features, diagnosis and treatment of oblique vaginal septum syndrome (OVSS). Methods: The clinical data of 80 patients with OVSS admitted to The Second Hospital of Hebei Medical University from July 2005 to July 2023 were retrospectively analyzed. According to the classification system of OVSS proposed by Female Genital Anomalies Study Group, Chinese Obstetricians and Gynecologists Association in 2021, the patients were divided into four groups. The clinical manifestations, accompanied urinary system abnormalities, diagnosis and treatment methods and treatment outcomes were observed. Results: According to the above classification system, among the 80 patients with OVSS, 35 patients (44%, 35/80) were categorized as type Ⅰ, 33 patients (41%, 33/80) were categorized as type Ⅱ, 2 patients (3%, 2/80) were categorized as type Ⅲ and 10 patients (13%, 10/80) were categorized as type Ⅳ. The main onset symptom of patients was periodic abdominal pain (70%, 56/80), vaginal bleeding (20%, 16/80), dysuria or fecal impaction (15%, 12/80), vaginal mucopurulent discharge (10%, 8/80). The morbidity of combined urinary system abnormalities was 88% (70/80), and the most common urinary system abnormality was ipsilateral renal agenesis (81%, 65/80). Bilateral kidneys were normal in 13% (10/80) patients, and 6% (5/80) were combined with other urinary system abnormalities. A total of 74 patients underwent vaginal oblique septectomy or septum excision. Five of the 10 patients with type Ⅳ underwent hysterectomy on the cervical atresia side, 4 patients received hysteroscopy combined with cervicoplasty+oblique septotomy or septum excision, and one patient selected delayed menstruation. Two patients underwent laparoscopic resection of the dysplasia kidney and ectopic ureter which opening to the vagina. Eleven patients with endometriosis cyst, hydrosalpinx or empyema underwent laparoscopic surgery. Conclusions: The main symptom of type Ⅰ and Ⅳ patients is abdominal pain, while the main symptom of type Ⅱ and Ⅲ patients is bleeding. Magnetic resonance imaging (MRI) has advantages in the evaluation of complex OVSS, and MRI is recommended before operation to exclude other axial reproductive tract dysplasia and complex urinary system dysplasia. If there is leakage of urine, vaginal discharge or complex deformity, it is necessary to multidisciplinary discussion and formulate a reasonable surgical plan. The first treatment is related to the prognosis of patients especially children, and should be highly valued.
The invention discloses a Chinese medicinal composition for treating periodontitis. Traditional Chinese medical science considers that the periodontitis belongs to the category of 'gingival atrophy' and 'toothache', and the pathogenesis is excessive pathogenic fire or hyperactivity of deficiency fire. Clinical researches conducted by the hospital in recent years indicate that on the basis of the therapeutic principle of clearing stomach and reducing pathogenic fire, detoxicating and reliving swelling, cooling blood and stopping bleeding, eliminating blood stasis and dredging collaterals and nourishing yin and tonifying kidney, the Chinese medicinal composition has a good treatment effect. Decoction is prepared from bupleurum, golden thread, liquoric root, Mongolian dandelion herb, platycodon root, Szechuan lovage rhizome, Chinese arborvitae twig, cortex moutan, peach seed, Chinese angelica, white paeony root, prepared rehmannia root, cinnamomvine and medlar. Clinical trials prove that: the cure rate is 82.4 percent, the effective rate is 96.3 percent and is obviously higher than that of a control group. In addition, the Chinese medicinal composition does not have toxic or side effect, and is high in anti-inflammatory capacity, quick in detumescence and safe and reliable in a curative effect.
Tuberculosis in animals is caused by members of the Mycobacterium tuberculosis complex (MTC), with the tuberculous granuloma being the main characteristic lesion. The macrophage is the main cell type involved in the development of the granuloma and presents a wide plasticity ranging from polarization to classically activated or pro-inflammatory macrophages (M1) or to alternatively activated or anti-inflammatory macrophages (M2). Thus, this study aimed to analyze macrophage polarization in granulomas from cattle and pig lymph nodes naturally infected with MTC. Tuberculous granulomas were microscopically categorized into four stages and a panel of myeloid cells (CD172a/calprotectin), M1 macrophage polarization (iNOS/CD68/CD107a), and M2 macrophage polarization (Arg1/CD163) markers were analyzed by immunohistochemistry. CD172a and calprotectin followed the same kinetics, having greater expression in late-stage granulomas in pigs. iNOS and CD68 had higher expression in cattle compared with pigs, and the expression was higher in early-stage granulomas. CD107a immunolabeling was only observed in porcine granulomas, with a higher expression in stage I granulomas. Arg1+ cells were significantly higher in pigs than in cattle, particularly in late-stage granulomas. Quantitative analysis of CD163+ cells showed similar kinetics in both species with a consistent frequency of immunolabeled cells throughout the different stages of the granuloma. Our results indicate that M1 macrophage polarization prevails in cattle during early-stage granulomas (stages I and II), whereas M2 phenotype is observed in later stages. Contrary, and mainly due to the expression of Arg1, M2 macrophage polarization is predominant in pigs in all granuloma stages.
A human yoga instructor will lead 10-14 yoga postures for a group of 20-25 older adults. The yoga session will also include meditation and centering exercises.
Invention applies to pharmacology, namely to medicine preparations containing albumens. The preparation consists of an active material, dissolver and auxiliary materials. Calcium tannin production waste is used for the active material, i.e. low activity (4-40V/mg) calcium tannin produced of a pig thyroid gland. Ingredients of the preparation are indicated below, as a mass percentage: calcium tannin production waste (4-40 V/mg activity) 0,125- 0, 0125, dissolver 84-98, binding material 1-19, powdering material 0, 8-1. The proposed preparation is used for the treatment of diseases related to skeleton changes.
BACKGROUND: The discovery of the hepatitis C virus (HCV) and direct-acting antiviral (DAA) drugs is one of the major milestones in the last 3 decades of medicine. These discoveries encouraged the World Health Organization (WHO) to set an ambitious goal to eliminate HCV by 2030, meaning "a 90% reduction in new cases of chronic HCV, a 65% reduction in HCV deaths, and treatment of 80% of eligible people with HCV infections."
SUMMARY: This review summarizes the key achievements from the discovery of HCV to the development of effective treatment and global elimination strategies. A better understanding of HCV structure, enzymes, and lifecycle led to the introduction of new drug targets and the discovery of DAA. Massive public health interventions are required, such as screening, access to care, treatment, and post-care follow-up, to make the most of DAA's potential. Screening must be supported by fast, accessible, sensitive, specific HCV diagnostic tests and noninvasive methods to determine the stage of liver disease. Linkage to care and treatment access are critical components of a comprehensive HCV elimination program, and decentralization plays a key role in ensuring their effectiveness.
KEY MESSAGES: Effective and simple screening strategies, rapid diagnostic tools, linkage to health care, and accessible treatment are key elements to achieving the WHO's goal. Incorporating treatment as prevention strategies into elimination programs together with preventive education and harm reduction interventions can have a profound and lasting impact on reducing both the incidence and prevalence of HCV. However, WHO's goal can be challenging to implement because of the need for high financial resources and strong political commitment.